


PHARMACEUTICAL 2023



GALECTIN THERAPEUTICS INC Rank 403 of 446







PHARMACEUTICAL 2023



GALECTIN THERAPEUTICS INC Rank 403 of 446

The relative strengths and weaknesses of GALECTIN THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GALECTIN THERAPEUTICS INC compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 15% points. The greatest weakness of GALECTIN THERAPEUTICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is -252%, being 295% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	20,552
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,012
Liabilities, Non-Current	66
Other Assets	733
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	40,401
Other Net Income	-424
Other Revenues	0
Property and Equipment	0
Research and Development	31,737
Selling, General and Administrative Expense	6,615

Output Variable	Value in 1000 USD
Assets	21,285
Liabilities	53,479
Expenses	38,352
Revenues	0
Stockholders Equity	-32,194
Net Income	-38,776
Comprehensive Net Income	-38,776
Economic Capital Ratio	-252%

